• Publications
  • Influence
Rifaximin therapy for patients with irritable bowel syndrome without constipation.
BACKGROUND Evidence suggests that gut flora may play an important role in the pathophysiology of the irritable bowel syndrome (IBS). We evaluated rifaximin, a minimally absorbed antibiotic, asExpand
  • 725
  • 36
  • PDF
American College of Gastroenterology Monograph on the Management of Irritable Bowel Syndrome and Chronic Idiopathic Constipation
Irritable bowel syndrome (IBS) and chronic idiopathic constipation ((CIC) also referred to as functional constipation) are two of the most common functional gastrointestinal disorders worldwide. IBSExpand
  • 422
  • 31
  • PDF
Placebos without Deception: A Randomized Controlled Trial in Irritable Bowel Syndrome
Background Placebo treatment can significantly influence subjective symptoms. However, it is widely believed that response to placebo requires concealment or deception. We tested whether open-labelExpand
  • 618
  • 23
  • PDF
Hydrogen and Methane-Based Breath Testing in Gastrointestinal Disorders: The North American Consensus
Objectives:Breath tests (BTs) are important for the diagnosis of carbohydrate maldigestion syndromes and small intestinal bacterial overgrowth (SIBO). However, standardization is lacking regardingExpand
  • 251
  • 20
  • PDF
American Gastroenterological Association medical position statement on constipation.
This document presents the official recommendations of the American Gastroenterological Association (AGA) on onstipation. It was drafted by the AGA Institute Medical Poition Panel, reviewed by theExpand
  • 251
  • 20
  • PDF
Chronic constipation.
N Engl J Med 2003;349:1360-8. Copyright © 2003 Massachusetts Medical Society. onstipation is a common symptom affecting between 2 percent 1,2 and 27 percent 3 of the population in Western countries.Expand
  • 598
  • 17
  • PDF
Components of placebo effect: randomised controlled trial in patients with irritable bowel syndrome
Objective To investigate whether placebo effects can experimentally be separated into the response to three components—assessment and observation, a therapeutic ritual (placebo treatment), and aExpand
  • 709
  • 16
  • PDF
Linaclotide for Irritable Bowel Syndrome With Constipation: A 26-Week, Randomized, Double-blind, Placebo-Controlled Trial to Evaluate Efficacy and Safety
OBJECTIVES:Linaclotide is a minimally absorbed peptide guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide treatment in patients withExpand
  • 296
  • 16
Efficacy of Prebiotics, Probiotics, and Synbiotics in Irritable Bowel Syndrome and Chronic Idiopathic Constipation: Systematic Review and Meta-analysis
OBJECTIVES:Irritable bowel syndrome (IBS) and chronic idiopathic constipation (CIC) are functional bowel disorders. Evidence suggests that disturbance in the gastrointestinal microbiota may beExpand
  • 468
  • 15
  • PDF
A 12-Week, Randomized, Controlled Trial With a 4-Week Randomized Withdrawal Period to Evaluate the Efficacy and Safety of Linaclotide in Irritable Bowel Syndrome With Constipation
OBJECTIVES:Linaclotide is a minimally absorbed guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide in patients with irritable bowelExpand
  • 264
  • 14
...
1
2
3
4
5
...